The estimated Net Worth of Christopher D. Roberts is at least $1.75 Milion dollars as of 3 May 2021. Christopher Roberts owns over 2,500 units of Black Diamond Therapeutics Inc stock worth over $34,941 and over the last 5 years he sold BDTX stock worth over $0. In addition, he makes $1,710,380 as Chief Scientific Officer at Black Diamond Therapeutics Inc.
Sign up
Christopher Roberts BDTX stock SEC Form 4 insiders trading
Christopher has made over 11 trades of the Black Diamond Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 2,500 units of BDTX stock worth $27,150 on 3 May 2021.
The largest trade he's ever made was exercising 5,000 units of Black Diamond Therapeutics Inc stock on 11 November 2020 worth over $54,300. On average, Christopher trades about 2,362 units every 19 days since 2020. As of 3 May 2021 he still owns at least 5,700 units of Black Diamond Therapeutics Inc stock.
You can see the complete history of Christopher Roberts stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Christopher Roberts biography
Dr. Christopher D. Roberts Ph.D. serves as Chief Scientific Officer of the Company. Prior to joining us, from April 2017 to August 2019, Dr. Roberts was Entrepreneur in Residence at S.R. One Limited, the corporate venture capital arm of GlaxoSmithKline plc. Previously, from April 2015 to March 2017, Dr. Roberts served as Vice President of Chemistry and Early Development at Syros Pharmaceuticals, Inc., a publicly-traded biotechnology company, where he built and led various discovery and development functions and helped guide two oncology assets into clinical development. Prior to joining Syros, from January 2009 to March 2015, Dr. Roberts held numerous positions of increasing responsibility at GSK, including Vice President and Head of the Host Defense Discovery Performance Unit. Dr. Roberts graduated with a B.A. in Chemistry from Whitworth University and earned his Ph.D. in Organic Chemistry from the University of California, Riverside, followed by a post-doctoral fellowship at the University of Bern, Switzerland.
What is the salary of Christopher Roberts?
As the Chief Scientific Officer of Black Diamond Therapeutics Inc, the total compensation of Christopher Roberts at Black Diamond Therapeutics Inc is $1,710,380. There are 2 executives at Black Diamond Therapeutics Inc getting paid more, with David Epstein having the highest compensation of $3,346,080.
How old is Christopher Roberts?
Christopher Roberts is 50, he's been the Chief Scientific Officer of Black Diamond Therapeutics Inc since 2019. There are 12 older and 7 younger executives at Black Diamond Therapeutics Inc. The oldest executive at Black Diamond Therapeutics Inc is Robert Ingram, 77, who is the Independent Chairman of the Board.
What's Christopher Roberts's mailing address?
Christopher's mailing address filed with the SEC is C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE, MA, 02142.
Insiders trading at Black Diamond Therapeutics Inc
Over the last 5 years, insiders at Black Diamond Therapeutics Inc have traded over $26,407,257 worth of Black Diamond Therapeutics Inc stock and bought 10,796,678 units worth $105,501,601 . The most active insiders traders include Ali Behbahani, Rajeev M. Shah a Capital Management, L.P.Ra .... On average, Black Diamond Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $899,443. The most recent stock trade was executed by Venture Capital Vi, L.P.Ver... on 28 August 2024, trading 221,600 units of BDTX stock currently worth $1,400,512.
What does Black Diamond Therapeutics Inc do?
black diamond therapeutics, inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. its lead product candidate is bdtx-189, an inhibitor of non-canonical and oncogenic mutations of erbb kinases epidermal growth factor receptor (egfr) and tyrosine-protein kinase. the company is also developing allosteric-egfr mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. the company was formerly known as aset therapeutics, inc. and changed its name to black diamond therapeutics, inc. in january 2018. black diamond therapeutics, inc. was founded in 2014 and is headquartered in cambridge, massachusetts.
What does Black Diamond Therapeutics Inc's logo look like?
Complete history of Christopher Roberts stock trades at Black Diamond Therapeutics Inc
Black Diamond Therapeutics Inc executives and stock owners
Black Diamond Therapeutics Inc executives and other stock owners filed with the SEC include:
-
David Epstein,
President, Chief Executive Officer, Director -
Thomas Leggett,
Chief Financial Officer -
Christopher Roberts,
Chief Scientific Officer -
Dr. David M. Epstein Ph.D.,
Co-Founder, Pres, CEO & Director -
Brent Hatzis-Schoch Esq., J.D.,
COO & Gen. Counsel -
Samarth Kulkarni,
Independent Director -
Dr. Rachel Wallach Humphrey M.D., Ph.D.,
Advisor -
Garry Menzel,
Independent Director -
Rajeev Shah,
Independent Director -
Ali Behbahani,
Independent Director -
Alexander Mayweg,
Director -
Bradley Bolzon,
Director -
Fang Ni,
Chief Business Officer -
Rachel Humphrey,
Chief Medical Officer -
Karsten Witt,
Senior Vice President - Non-Clinical Development -
Elizabeth Buck,
Executive Vice President - Discovery and Translational Services -
Brent Hatzis-Schoch,
Chief Operating Officer, General Counsel -
Robert Ingram,
Independent Chairman of the Board -
Tai-An Lin Ph.D.,
VP & Head of Biology -
Dr. Karsten Witt M.D.,
Sr. VP of Clinical Devel. & Interim Chief Medical Officer -
Dr. Christopher D. Roberts Ph.D.,
Advisor -
Erika Jones,
VP of Fin., Corp. Controller & Principal Accounting Officer -
Dr. Fang Ni Pharm.D.,
CFO, Principal Financial Officer and Chief Bus. Officer -
Dr. Elizabeth Buck Ph.D.,
Co-Founder & Chief Scientific Officer -
James E Deerfield Mgmt L.P....,
-
Sergey Yurasov,
CHIEF MEDICAL OFFICER -
Shannon Campbell,
-
Prakash Raman,
-
Venture Capital Vi, L.P.Ver...,
-
Biomedical Innovation Maste...,
10% owner -
Venture Capital Vi, L.P.Ver...,
-
Erika Jones,
SEE REMARKS -
Wendy L Dixon,
-
Growth N Vbb Biotech Ag Bio...,
-
Kapil Dhingra,
-
Capital Management, L.P.Ra ...,
-
Mark A. Velleca,
PRESIDENT & CEO